Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: Can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?

Roberto M. Lemoli, Alessandra D'Addio

Research output: Contribution to journalArticle

Abstract

The majority of patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction/consolidation chemotherapy. The optimal post-remission treatment is still a matter of debate. However, the intensification of post-remission treatment, including high-dose chemotherapy followed by infusion of autologous or allogeneic stem cells, has progressively increased, considering the high risk of relapse without any further post-remission therapy. The most effective conditioning regimen before hematopoietic stem cell transplantation (HSCT) remains controversial. The combination of busulfan and cyclophosphamide (BU-Cy) is the most used conditioning treatment as its anti-leukemic activity is well established.

Original languageEnglish
Pages (from-to)172
Number of pages1
JournalRevista Brasileira de Hematologia e Hemoterapia
Volume33
Issue number3
DOIs
Publication statusPublished - Jun 2011

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: Can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?'. Together they form a unique fingerprint.

Cite this